NO20076239L - Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom - Google Patents

Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom

Info

Publication number: NO20076239L
Authority: NO; Norway
Prior art keywords: methods; alzheimer; disease; treatment; immunogenic fragment
Prior art date: 2005-05-05

Application number

NO20076239A

Other languages

English (en)

Norwegian (no)

Inventor

John W Shiver

Victor M Garsky

Xiaoping Liang

Joseph G Joyce

Paul M Keller

Gene Kinney

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-05

Filing date

2007-12-04

Publication date

2008-01-30

2007-12-04 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2008-01-30 Publication of NO20076239L publication Critical patent/NO20076239L/no

Links

238000000034 method Methods 0.000 title abstract 3
208000024827 Alzheimer disease Diseases 0.000 title abstract 2
239000000863 peptide conjugate Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
230000002265 prevention Effects 0.000 title 1
239000012634 fragment Substances 0.000 abstract 4
230000002163 immunogen Effects 0.000 abstract 4
208000037259 Amyloid Plaque Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000003028 elevating effect Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20076239A 2005-05-05 2007-12-04 Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom NO20076239L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US67788605P	2005-05-05	2005-05-05
PCT/US2006/016481 WO2006121656A2 (en)	2005-05-05	2006-05-01	Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease

Publications (1)

Publication Number	Publication Date
NO20076239L true NO20076239L (no)	2008-01-30

Family

ID=37019042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20076239A NO20076239L (no)	2005-05-05	2007-12-04	Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom

Country Status (16)

Country	Link
US (2)	US7850973B2 (pt)
EP (2)	EP1879613B1 (pt)
JP (1)	JP2008540417A (pt)
KR (1)	KR20080005260A (pt)
CN (1)	CN101171031B (pt)
AT (1)	ATE535252T1 (pt)
AU (1)	AU2006246382A1 (pt)
BR (1)	BRPI0610093A2 (pt)
CA (1)	CA2607868A1 (pt)
IL (1)	IL186793A0 (pt)
MX (1)	MX2007013825A (pt)
NO (1)	NO20076239L (pt)
NZ (1)	NZ562434A (pt)
RU (1)	RU2406529C2 (pt)
WO (1)	WO2006121656A2 (pt)
ZA (1)	ZA200708635B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
BRPI0619249A2 (pt)	2005-11-30	2011-09-20	Abbott Lab	anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt)	2005-11-30	2014-04-29	Abbvie Inc	Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
WO2007064917A2 (en) *	2005-11-30	2007-06-07	Abbott Laboratories	Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
PE20090329A1 (es) *	2007-05-30	2009-03-27	Abbott Lab	Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
EP2527366B1 (en) *	2007-06-12	2017-08-16	AC Immune S.A.	Monoclonal anti beta amyloid antibody
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
EP2020602A1 (en) *	2007-08-02	2009-02-04	Araclon Biotech	High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
EP2586795B1 (en)	2007-10-05	2018-05-16	Genentech, Inc.	Use of anti-amyloid beta antibody in ocular diseases
ITMI20071975A1 (it) *	2007-10-12	2009-04-13	Fond I R C C S Istituto Neur O	Prodotti e loro uso per la diagnosi prevenzione e-o cura di patologie umane e-o animali caraterizzate dalla anomala deposizione di sostanza b-amiloide e-o similamiloide in organi e tesstui umani e-o animali e metodo di screening per la determinazione
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
WO2009054537A1 (ja)	2007-10-25	2009-04-30	Kagoshima University	アミロイドβペプチドのミミック分子を用いたペプチドワクチン
CA2729414C (en) *	2008-07-01	2017-08-22	De Staat Der Nederlanden, Vert. Door De Minister Van Vws	Vaccine against amyloid folding intermediate
JP2011527681A (ja) *	2008-07-08	2011-11-04	メルク・シャープ・エンド・ドーム・コーポレイション	アルツハイマー病治療用ワクチン
EP2149380A1 (en) *	2008-07-29	2010-02-03	Medivet Pharma, S.L.	Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
US8524863B2 (en) *	2008-10-06	2013-09-03	Commonwealth Scientific And Industrial Research Organisation	Amyloid-beta peptide crystal structure
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
EP2258398A1 (en) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Albumin-amyloid peptide conjugates and uses thereof
CA3239368A1 (en) *	2009-06-10	2010-12-16	New York University	Immunological targeting of pathological tau proteins
WO2011106732A1 (en)	2010-02-25	2011-09-01	Wyeth Llc	Pet monitoring of ab-directed immunotherapy
EP2558494B1 (en)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta binding proteins
AU2011282536B2 (en)	2010-07-30	2015-12-24	Ac Immune S.A.	Safe and functional humanized anti beta-amyloid antibody
CN105348387B (zh)	2010-08-14	2020-08-25	Abbvie 公司	β淀粉样蛋白结合蛋白
US20120328605A1 (en) *	2010-10-27	2012-12-27	Daniel Larocque	Compositions and uses
WO2012072611A1 (de) *	2010-11-29	2012-06-07	Philipps-Universität Marburg	SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
WO2013059322A2 (en) *	2011-10-17	2013-04-25	Lawrence Steinman	Amyloid beta peptide as a therapy for inflammation
CN106794236B (zh) *	2014-04-15	2021-09-03	格里菲斯大学	A群链球菌疫苗
JP6913018B2 (ja)	2014-07-08	2021-08-04	ニューヨーク・ユニバーシティ	タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
CN108135986B (zh)	2015-08-13	2022-07-29	纽约大学	对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
ES2571055B1 (es) *	2016-02-15	2016-12-28	Araclon Biotech, S.L.	Conjugado amiloide y usos y procedimientos del mismo
WO2017179646A1 (ja) *	2016-04-14	2017-10-19	Ｔａｏヘルスライフファーマ株式会社	アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物
KR101898623B1 (ko)	2016-11-10	2018-09-13	주식회사 브레인숲	종이 완구블록
EP3658172A4 (en)	2017-07-25	2021-05-05	TrueBinding, Inc.	TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
EA202091012A1 (ru)	2017-10-25	2020-08-27	Янссен Фармасьютикалз, Инк.	Композиции фосфорилированных тау-пептидов и их применения
RU2679059C1 (ru) *	2018-04-17	2019-02-05	Александр Олегович Морозов	Пептид и способ лечения болезни альцгеймера
RU2679080C1 (ru) *	2018-04-17	2019-02-05	Александр Олегович Морозов	Пептид и способ лечения болезни альцгеймера
CN113711036B (zh)	2019-01-30	2025-03-18	真和制药有限公司	抗gal3抗体及其用途
CN113710269A (zh)	2019-02-08	2021-11-26	Ac免疫有限公司	磷酸化Tau肽疫苗的安全施用方法
CN116157151A (zh)	2020-05-26	2023-05-23	真和制药有限公司	通过阻断半乳凝素-3治疗炎性疾病的方法
CN116063382B (zh) *	2022-11-17	2024-11-05	山东大学	一种具有三阶非线性光学性能的多肽材料及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5494808A (en)	1994-09-15	1996-02-27	Merck & Co., Inc.	Defined medium OMPC fermentation process
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) *	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
JP3854481B2 (ja) *	2000-11-17	2006-12-06	三菱重工業株式会社	湿式排煙脱硫装置、及び、湿式排煙脱硫方法
ES2279869T3 (es) *	2001-06-20	2007-09-01	Ramot At Tel Aviv University Ltd.	Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes.
MY144532A (en) *	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
MXPA05008156A (es)	2003-02-01	2005-09-30	Neuralab Ltd	Inmunizacion activa para generar anticuerpos para beta-a soluble.
UA93854C2 (ru) *	2003-12-17	2011-03-25	Вайет Ллк	Иммуногенный конъюгат и способ его получения

2006
- 2006-05-01 AU AU2006246382A patent/AU2006246382A1/en not_active Abandoned
- 2006-05-01 MX MX2007013825A patent/MX2007013825A/es active IP Right Grant
- 2006-05-01 CN CN2006800153890A patent/CN101171031B/zh not_active Expired - Fee Related
- 2006-05-01 EP EP06751930A patent/EP1879613B1/en not_active Expired - Lifetime
- 2006-05-01 NZ NZ562434A patent/NZ562434A/en not_active IP Right Cessation
- 2006-05-01 CA CA002607868A patent/CA2607868A1/en not_active Abandoned
- 2006-05-01 BR BRPI0610093-7A patent/BRPI0610093A2/pt not_active IP Right Cessation
- 2006-05-01 AT AT06751930T patent/ATE535252T1/de active
- 2006-05-01 US US11/919,897 patent/US7850973B2/en not_active Expired - Fee Related
- 2006-05-01 EP EP10181823A patent/EP2269633A1/en not_active Withdrawn
- 2006-05-01 RU RU2007145052/10A patent/RU2406529C2/ru not_active IP Right Cessation
- 2006-05-01 JP JP2008510087A patent/JP2008540417A/ja active Pending
- 2006-05-01 KR KR1020077025682A patent/KR20080005260A/ko not_active Ceased
- 2006-05-01 WO PCT/US2006/016481 patent/WO2006121656A2/en not_active Ceased
2007
- 2007-10-10 ZA ZA2007/08635A patent/ZA200708635B/en unknown
- 2007-10-18 IL IL186793A patent/IL186793A0/en unknown
- 2007-12-04 NO NO20076239A patent/NO20076239L/no not_active Application Discontinuation
2010
- 2010-11-08 US US12/907,493 patent/US20110052611A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20080005260A (ko)	2008-01-10
JP2008540417A (ja)	2008-11-20
NZ562434A (en)	2010-04-30
US20110052611A1 (en)	2011-03-03
US20090098155A1 (en)	2009-04-16
US7850973B2 (en)	2010-12-14
RU2406529C2 (ru)	2010-12-20
ZA200708635B (en)	2008-10-29
AU2006246382A1 (en)	2006-11-16
CN101171031B (zh)	2011-09-28
BRPI0610093A2 (pt)	2008-12-09
WO2006121656A3 (en)	2007-01-04
CA2607868A1 (en)	2006-11-16
EP1879613B1 (en)	2011-11-30
ATE535252T1 (de)	2011-12-15
EP2269633A1 (en)	2011-01-05
WO2006121656A2 (en)	2006-11-16
IL186793A0 (en)	2008-02-09
MX2007013825A (es)	2008-01-18
EP1879613A2 (en)	2008-01-23
CN101171031A (zh)	2008-04-30
RU2007145052A (ru)	2009-06-10

Legal Events

Date	Code	Title	Description
2015-12-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
ZA200708635B (en)	2008-10-29	Peptide conjugate compositions and methods for the prevention and treatment of alzheimers disease
ES2407429T3 (es)	2013-06-12	Vacuna terapéurica
EP2547364B1 (en)	2016-12-14	Peptides, conjugates and method for increasing immunogenicity of a vaccine
AR024074A1 (es)	2002-09-04	FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS.
EA200601761A1 (ru)	2007-06-29	Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
JP2008508859A5 (pt)	2008-07-10
JP6941321B2 (ja)	2021-09-29	疾患の要因となる生体内タンパク質を標的とするコンジュゲートワクチン
IL164643A (en)	2011-11-30	Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease
CY1117387T1 (el)	2017-04-26	ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
RU2011120706A (ru)	2012-11-27	Композиции вакцин, содержащие мутированный белок, связывающий фактор н
CN107073088A (zh)	2017-08-18	免疫原性糖肽、包含所述糖肽的组合物及其用途
NO20071267L (no)	2007-05-09	Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer
HUP0401534A2 (hu)	2004-11-29	Módosított humán IX. faktor
MXPA05011110A (es)	2006-01-24	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
EP2305286A2 (en)	2011-04-06	Treatment for Alzeimer's disease
EA200701519A1 (ru)	2008-02-28	Живая аттенуированная ротавирусная вакцина для перорального введения
WO2005072777A3 (en)	2006-06-15	Conjugates of amyloid proteins as vaccines for amyloid-related diseases
EP2300494A1 (en)	2011-03-30	Anti-amyloid immunogenic compositions, methods and uses
WO2005120558A3 (en)	2007-03-29	Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
ES2701084T3 (es)	2019-02-20	Compuestos inmunogénicos que comprenden péptido gp41 de VIH acoplado a proteína portadora CRM197
JP2017508006A5 (pt)	2018-02-22
JP2015529677A5 (pt)	2016-10-20
JP5661744B2 (ja)	2015-01-28	腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
CN106163540A (zh)	2016-11-23	用于治疗蛋白病或构象病的聚集蛋白和分子伴侣的组合
WO2005012330A3 (en)	2005-09-09	AMYLOID β-PEPTIDE AND METHODS OF USE